A Single Center, Randomized, Open Label, Crossover Study With Ticagrelor and Prasugrel to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

Trial Profile

A Single Center, Randomized, Open Label, Crossover Study With Ticagrelor and Prasugrel to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 31 Aug 2017 to 31 Oct 2017.
    • 18 Jul 2017 Planned primary completion date changed from 31 Jul 2017 to 31 Oct 2017.
    • 18 Jul 2017 Planned initiation date changed from 28 Feb 2017 to 28 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top